EUCTR2005-005378-58-IT进行中（未招募）不适用
Inhaled pre-prandial human insulin with the AERx iDMS versus s.c. insulin aspart in type 2 diabetes A 52-week, open-label, multicentre, randomised trial followed by 52-week extension and 12-week re-randomised extension to investigate safety and efficacy - ND
OVO NORDISK0 个研究点目标入组 710 人开始时间: 2006年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 710
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •6.2 Inclusion Criteria 1. Informed consent obtained before any trial-related activities Trial-related activities are any procedure that would not have been performed during normal management of the subject . 2. Diagnosis of type 2 diabetes according to clinical judgement 3. Current treatment with any regimen of insulin for 8805; 3 months with or without a maximum of one OAD 4. Able and willing to be treated with a basal regimen once or twice daily and bolus regimen 3 times per day 5. Males and females, age 8805; 18 years 6. Body mass index of BMI 8804; 40.0 kg/m2 7. HbA1c 8804; 11.0 analysis from central laboratory 8. Able and willing to perform self-monitoring of plasma glucose according to the protocol and to keep a diary
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous participation in this trial. Participation is defined as randomisation 2. Pregnant or positive pregnancy test at screening, nursing mother, or unwillingness to use adequate contraception appropriate methods include abstinence and the following methods diaphragm, condom, by partner , intrauterine device, sponge, spermacide or oral contraceptives 3. Total daily insulin dosage 100 Units 4. Current smoking or smoking within the last 6 months regular smoking defined as one cigarette or an equivalent amount of smoking tobacco per day or a positive urine cotinine test on screening laboratory test. Subjects using non-inhalable tobacco products can be included despite a positive urine cotinine test 5. Chest X-ray with any clinically significant abnormalities evaluated by a radiologist 6. Unresolved symptoms and signs of an upper respiratory tract infection URI within 3 weeks prior to screening 7. Current acute or chronic pulmonary disease excluding asthma including chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, sarcoidosis, and pulmonary fibrosis 8. Positive screening for Hepatitis B antigen or Hepatitis C antibody 9. Positive screening for Human Immune deficiency Virus HIV 10. History of hypoglycaemic unawareness and/or two or more severe hypoglycaemic episodes in the past year as judged by the Investigator 11. Treatment with systemic steroids within the past 2 months prior to screening 12. Impaired hepatic function defined as screening aspartate aminotransferase AST or alanine aminotransferase ALT 8805; 2.5 times upper normal range one re-test analysed at the central laboratory within one week is permitted with the last sample being conclusive 13. Known or suspected allergy to any trial products or related products 14. Clinically significant, active or over the past 12 months disease of the cardiovascular, gastrointestinal, neurological, genitourinary, haematological systems, or has severe uncontrolled treated or untreated hypertension systolic blood pressure 8805; 180 mmHg or sitting diastolic blood pressure 8805; 100 or history of proliferative retinopathy or maculopathy requiring treatment 15. Renal insufficiency creatinine 8805; 2 mg/dL; 8805; 180 mol/L 16. Any conditions that the Investigator judges would interfere with trial participation or evaluation of results 17. Current addiction to alcohol or substances of abuse as judged by the Investigator 18. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation in the trial 19. Participated in another clinical trial and received an investigational drug within the last 4 weeks or received previous treatment with pulmonary insulin other than subjects treated with AERx for more than a total of seven days
研究者
相似试验
进行中（未招募）
1 期
Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: A 52-week, open-label, multicentre, randomised, parallel trial to investigate long-term safetyType 1 DiabetesType 2 DiabetesCOPDMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-004731-29-SKovo Nordisk A/S225
进行中（未招募）
1 期
Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safetyType 1 diabetesType 2 diabetesAsthmaMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-004622-81-SKovo Nordisk A/S225
进行中（未招募）
1 期
Inhaled pre-prandial human insulin with the AERx® iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to investigate efficacy and safetyType II diabetesMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-000796-15-FRovo Nordisk A/S
进行中（未招募）
1 期
Inhaled pre-prandial human insulin with the AERx® iDMS versus s.c. insulin aspart in type 2 diabetes: A 104-week, open-label, multicentre, randomised trial followed by 12-week re-randomised extension to investigate safety and efficacyMedDRA version: 8.1Level: LLTClassification code 10012601Diabetes MellitusEUCTR2005-005378-58-GBovo Nordisk A/S
进行中（未招募）
不适用
Inhaled pre-prandial human insulin with the AERx® iDMS versus s.c. insulin aspart in type 2 diabetes: A 104-week, open-label, multicentre, randomised trial followed by 12-week re-randomised extension to investigate safety and efficacyMedDRA version: 8.1Level: LLTClassification code 10012601Diabetes MellitusEUCTR2005-005378-58-DKovo Nordisk A/S710